Evaluation of Salmonella enterica type III secretion system effector proteins as carriers for heterologous vaccine antigens

Infection and Immunity

Volumn 80, Issue 3, 2012, Pages 1193-1202

  Hegazy, Wael Abdel Halim ^a,c,d   Xu, Xin ^b   Metelitsa, Leonid ^b   Hensel, Michael ^c  

^a UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^b CENTER FOR CELL AND GENE THERAPY   (United States)

^c UNIVERSITY OF OSNABRÜCK   (Germany)

^d Zagazig University   (Egypt)

Author keywords

[No Author keywords available]

Indexed keywords

HYBRID PROTEIN; LISTERIOLYSIN; OVALBUMIN; RECOMBINANT VACCINE; SALMONELLOSIS VACCINE; SIFA LISA FUSION PROTEIN; SSEF LISA FUSION PROTEIN; SSEJ LISA FUSION PROTEIN; SSEL LISA FUSION PROTEIN; STEC LISA FUSION PROTEIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIGEN SPECIFICITY; ARTICLE; BACTERIAL STRAIN; BACTERIAL TRANSLOCATION; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOSOL; DRUG DESIGN; DRUG EFFICACY; DRUG SPECIFICITY; ENDOSOME; FEMALE; HOST CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; SALMONELLA ENTERICA; T LYMPHOCYTE ACTIVATION; TYPE III SECRETION SYSTEM;

ANIMALS; ANTIGENS; BACTERIAL TOXINS; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; FEMALE; HEAT-SHOCK PROTEINS; HEMOLYSIN PROTEINS; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; OVALBUMIN; PROTEIN TRANSPORT; RECOMBINANT FUSION PROTEINS; SALMONELLA ENTERICA; SALMONELLA VACCINES; T-LYMPHOCYTES; VACCINATION; VACCINES, ATTENUATED; VACCINES, SYNTHETIC; VIRULENCE FACTORS;

EID: 84863275571     PISSN: 00199567     EISSN: 10985522     Source Type: Journal    
DOI: 10.1128/IAI.06056-11     Document Type: Article

References (26)

1. Abrahams GL, Hensel M. 2006. Manipulating cellular transport and immune responses: dynamic interactions between intracellular Salmonella enterica and its host cells. Cell. Microbiol. 8:728-737.
2. Aizawa SI. 2001. Bacterial flagella and type III secretion systems. FEMS Microbiol. Lett. 202:157-164.
3. Cheminay C, Hensel M. 2008. Rational design of Salmonella recombinant vaccines. Int. J. Med. Microbiol. 298:87-98.
4. Cornelis GR. 2006. The type III secretion injectisome. Nat. Rev. Microbiol. 4:811-825.
5. Gerlach RG, Hensel M. 2007. Salmonella pathogenicity islands in host specificity, host pathogen-interactions and antibiotics resistance of Salmonella enterica. Berl. Munch. Tierarztl. Wochenschr. 120:317-327.
6. Ghosh P. 2004. Process of protein transport by the type III secretion system. Microbiol. Mol. Biol. Rev. 68:771-795.
7. Halici S, Zenk SF, Jantsch J, Hensel M. 2008. Functional analysis of the Salmonella pathogenicity island 2-mediated inhibition of antigen presentation in dendritic cells. Infect. Immun. 76:4924-4933.
8. Hansen-Wester I, Stecher B, Hensel M. 2002. Type III secretion of Salmonella enterica serovar Typhimurium translocated effectors and SseFG. Infect. Immun. 70:1403-1409.
9. Haraga A, Ohlson MB, Miller SI. 2008. Salmonellae interplay with host cells. Nat. Rev. Microbiol. 6:53-66.
10. Hogquist KA, et al. 1994. T cell receptor antagonist peptides induce positive selection. Cell 76:17-27.
11. Husseiny MI, Wartha F, Hensel M. 2007. Recombinant vaccines based on translocated effector proteins of Salmonella pathogenicity island 2. Vaccine 25:185-193.
12. Ibarra JA, Steele-Mortimer O. 2009. Salmonella-the ultimate insider. Salmonella virulence factors that modulate intracellular survival. Cell. Microbiol. 11:1579-1586.
13. Karttunen J, Sanderson S, Shastri N. 1992. Detection of rare antigenpresenting cells by the lacZ T-cell activation assay suggests an expression cloning strategy for T-cell antigens. Proc. Natl. Acad. Sci. U. S. A. 89:6020-6024.
14. Lara-Tejero M, Pamer EG. 2004. T cell responses to Listeria monocytogenes. Curr. Opin. Microbiol. 7:45-50.
15. Mastroeni P, Chabalgoity JA, Dunstan SJ, Maskell DJ, Dougan G. 2001. Salmonella: immune responses and vaccines. Vet. J. 161:132-164.
16. Medina E, Guzman CA. 2001. Use of live bacterial vaccine vectors for antigen delivery: potential and limitations. Vaccine 19:1573-1580.
17. Mollenkopf H, Dietrich G, Kaufmann SH. 2001. Intracellular bacteria as targets and carriers for vaccination. Biol. Chem. 382:521-532.
18. Panthel K, et al. 2005. Salmonella pathogenicity island 2-mediated overexpression of chimeric SspH2 proteins for simultaneous induction of antigen-specific CD4 and CD8 T cells. Infect. Immun. 73:334-341.
19. Panthel K, Meinel KM, Sevil Domenech VE, Trülzsch K, Rüssmann H. 2008. Salmonella type III-mediated heterologous antigen delivery: a versatile oral vaccination strategy to induce cellular immunity against infectious agents and tumors. Int. J. Med. Microbiol. 298:99-103.
20. Pasetti MF, Simon JK, Sztein MB, Levine MM. 2011. Immunology of gut mucosal vaccines. Immunol. Rev. 239:125-148.
21. Rüssmann H. 2003. Bacterial type III translocation: a unique mechanism for cytosolic display of heterologous antigens by attenuated Salmonella. Int. J. Med. Microbiol. 293:107-112.
22. Sundquist M, Rydstrom A, Wick MJ. 2004. Immunity to Salmonella from a dendritic point of view. Cell. Microbiol. 6:1-11.
23. Xiong G, et al. 2010. Novel cancer vaccine based on genes of Salmonella pathogenicity island 2. Int. J. Cancer 126:2622-2634.
24. Xu X, Hensel M. 2010. Systematic analysis of the SsrAB virulon of Salmonella enterica. Infect. Immun. 78:49-58.
25. Xu X, Husseiny MI, Goldwich A, Hensel M. 2010. Efficacy of intracellular activated promoters for generation of Salmonella-based vaccines. Infect. Immun. 78:4828-4838.
26. Yrlid U, Wick MJ. 2002. Antigen presentation capacity and cytokine production by murine splenic dendritic cell subsets upon Salmonella encounter. J. Immunol. 169:108-116.